Copper peptides have quietly moved from dermatology journals onto skincare shelves, and two names have recently started trending alongside them: GLOW and KLOW. Both are multi-peptide blends built around the same copper peptide, GHK-Cu. Here is what each ingredient is, what the research shows, and where the evidence is still thin.
GHK-Cu: the copper peptide your body already makes
GHK is a three-amino-acid peptide (glycine-histidine-lysine) that binds copper tightly, forming GHK-Cu. It was first isolated from human blood plasma in 1973 by Dr Loren Pickart, who noticed that plasma from younger people made aging liver tissue behave more youthfully, and traced part of that effect to GHK.
Two findings explain the interest in skin:
- It declines with age. Plasma GHK levels are around 200 ng/mL at age 20 and fall to roughly 80 ng/mL by age 60.
- It stimulates the skin’s building materials. In a 1988 study, GHK-Cu stimulated collagen production in fibroblast cultures, the cells that make the skin’s structural scaffolding. Later work linked it to glycosaminoglycans (which hold moisture), wound healing in animal models, and the balance of enzymes that break down and rebuild tissue.
More recent gene-expression analyses suggest GHK influences a broad set of genes involved in tissue repair, inflammation and antioxidant defence. Topical GHK-Cu has been used in cosmetic formulations for years, and small studies have reported improvements in skin density and fine lines.
Why build a blend?
Skin and tissue repair involves several overlapping steps: calming inflammation, growing new blood vessels, moving repair cells into place and rebuilding collagen. No single peptide covers all of them, so researchers have started studying combinations.
GLOW combines three peptides in a single vial:
| Component | Main research focus |
| GHK-Cu | Collagen and matrix remodelling |
| BPC-157 | Tissue repair and new blood vessel growth (rodent studies) |
| TB-500 | Cell migration, from the actin-binding protein thymosin beta-4 |
KLOW adds a fourth:
| Component | Main research focus |
| KPV | Anti-inflammatory signalling, a fragment of alpha-MSH |
The logic is complementary mechanisms: matrix rebuilding, blood supply, cell movement and, in KLOW’s case, inflammation control. Laboratories studying tissue remodelling use research-grade GLOW peptide and KLOW peptide blends to explore how those pathways interact.
Where the evidence stops
It is important to separate three different things:
- Topical GHK-Cu skincare is a cosmetic ingredient with a long track record in serums and creams.
- Individual research peptides (BPC-157, TB-500, KPV) have promising data, but mostly from animal and cell studies, and none is an approved medicine.
- The blends themselves have not been tested as combinations in published clinical trials. Their rationale is built from the individual components.
Research-grade blends are supplied for laboratory use only and are not skincare products.
What actually works for skin today
If your goal is healthier-looking skin, the best-supported steps remain daily broad-spectrum sunscreen, a retinoid, adequate sleep and not smoking. A well-formulated topical copper peptide serum is a reasonable addition, and the research behind GHK-Cu is one of the more genuinely interesting stories in skin science.
References
- Pickart L, Thaler MM. Tripeptide in human serum which prolongs survival of normal liver cells and stimulates growth in neoplastic liver. Nature New Biology. 1973;243(124):85-87.
- Maquart FX, et al. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Letters. 1988;238(2):343-346.
- Pickart L, Vasquez-Soltero JM, Margolina A. GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. BioMed Research International. 2015;2015:648108.
This article is for educational purposes only. Research peptides referenced are supplied for laboratory research and are not for human use.